

FOI – 2040

28th November 2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in October 2023 (or latest available month) by the Dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Dupilumab (Dupixent)
- Omalizumab (Xolair)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)

• Abrocitinib (Cibinqo)	0
• Baricitinib (Olumiant)	1
• Dupilumab (Dupixent)	98
• Omalizumab (Xolair)	34
• Tralokinumab (Adtralza)	2
• Upadacitinib (Rinvoq)	12

Q2. How many patients were treated in October 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

• Benralizumab (Fasenra)	0
• Dupilumab (Dupixent)	0
• Mepolizumab (Nucala)	0
• Omalizumab (Xolair)	0
• Reslizumab (Cinqaero)	0
• Tezepelumab (Tezspire)	0

Data provided by Pharmacy Department

Email: foi.team@southerntrust.hscni.net